Alnylam Acquires Sirna Therapeutics from Merck for $175M Upfront Payment in Cash, Stock
January 13, 2014 at 05:53 AM EST
Alnylam Pharmaceuticals (Nasdaq: ALNY ) announced Sunday the acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, comprising intellectual property and RNAi assets including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate
